An interventional study of ASV and without Autoset CS2 in Heart Failure and Cheyne Stokes Respiration, sponsored by University of Oslo. Completed at 1 site in Norway. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-12-03.
Sponsored by University of Oslo · Not applicable, Interventional, and Treatment
An investigation where patients with chronic heart failure and cheyne stokes respiration, treated with adapitve servo ventilator, will improve their cardiac function and quality of life.
Chronic heart failure (HF) is one of the most important public health problems in cardiovascular medicine.
Several patients with chronic heart failure also has Cheyne Stokes respiration pattern. Earlier studies have shown that this respiration pattern improves with Adaptive servo ventilator. We wish to investigate wether this leads to improved cardiac function.
23 studies on the registry are indexed under Cheyne-Stokes Respiration; 1 is open to participants now.
This study's enrollment of 40 is below the median of 48 across 20 interventional studies indexed under Cheyne-Stokes Respiration.
Browse Cheyne-Stokes Respiration studies →University of Oslo is the lead sponsor of 176 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The patients use ASV
Device: ASV · Other: without Autoset CS2
Patients without ASV
Other: without Autoset CS2
Adaptive servo ventilator
Also known as: AutoSet CS2
without Autoset CS2
Ejection fraction (measured with echocardiography) and inflammatory markers
Time frame: 3 months
6 minutes walking test Quality of life Changes in cathecolamines Altered frequency of arrythmias
Time frame: 3 months
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oslo